Media Thread, page-11891

I’m hearing people express concern regarding the slow pace of Oasis. Only the second patient dosed since first patient in October. Given the trial has an almost identical recruitment basis as the MAST VAXINIA trial, it would appear one trial is being prioritised(MAST VAXINIA).
Perhaps we need to prioritise the trial going through lengthy dose escalation process over Oasis which began later and is starting at the optimal dose. Perhaps both trials will progress faster now and Oasis might catch up.
Bring on the data and now that we have the attention of the world’s Oncologists, perhaps progress will be swift from here. One more consideration: I don’t think we are the only company looking for trial participants with late stage cancer.
Good luck team Imugene and best of outcomes for patients.